News Medical on MSN5d
Gene therapy breakthrough offers hope for severe Dravet syndrome casesAAV-Navβ1 gene therapy effectively reduces seizures and prolongs life in a mouse model of SCN1B-linked Dravet syndrome, ...
The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...
GlobalData on MSN4d
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatmentBiogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet ...
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million ...
Biogen receives exclusive rights to commercialize zorevunersen outside U.S., Europe, and Japan.
Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage ...
Biogen (NASDAQ:BIIB) and Stoke Therapeutics (NASDAQ:STOK) said on Tuesday they are collaborating to develop and commercialize ...
Biogen will receive rights to commercialize zorevunersen outside the US, Canada, and Mexico, paying $165 million upfront and other milestone payments.
Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of ...
The proposed study will evaluate two loading doses of 70mg followed by two maintenance doses of 45mg over 52-weeks compared to sham in children and adolescents ages 2 to <18 with Dravet syndrome.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback